| |
| |
| Exchange: |
Nasdaq National Market |
| Security
Type: |
Common |
| Shares
Out: |
254,036,000 |
| Market
Cap: |
N/A |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$22.93 - $22.93 |
|
| Level
I Sector: |
Health Care |
| Level
II Sector: |
Drugs |
| Level
III Sector: |
Drug Manufacturers - Other |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
0 |
| Total Buy Value |
$0 |
$0 |
$0 |
$0 |
| Total People Bought |
0 |
0 |
0 |
0 |
| Total Buy Transactions |
0 |
0 |
0 |
0 |
| Total Shares Sold |
0 |
0 |
0 |
0 |
| Total Sell Value |
$0 |
$0 |
$0 |
$0 |
| Total People Sold |
0 |
0 |
0 |
0 |
| Total Sell Transactions |
0 |
0 |
0 |
0 |
| End Date |
2024-02-15 |
2023-11-14 |
2023-05-16 |
2022-05-16 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Alpinvest Partners Later Stage Co-Investments Cust |
*See Remarks |
– – • |
2010-09-23 |
4 |
S |
$22.85 |
$8,985,465 |
D/D |
(393,237) |
2,300,673 |
|
- |
|
| Alpinvest Partners Later Stage Co-Investments Cust |
*See Remarks |
– – • |
2010-09-22 |
4 |
S |
$22.92 |
$11,030,021 |
D/D |
(481,240) |
2,693,910 |
|
- |
|
| Gilligan Claire A |
Senior V.P. Global Quality |
• – – |
2010-09-22 |
4 |
S |
$23.05 |
$22,034 |
D/D |
(956) |
55,555 |
|
- |
|
| Howard Alvin D |
Sr. V.P., Regulatory Affairs |
• – – |
2010-09-22 |
4 |
S |
$23.05 |
$32,775 |
D/D |
(1,422) |
208,042 |
|
- |
|
| Cross Leland H |
Senior V.P., Tech. Operations |
• – – |
2010-09-22 |
4 |
S |
$23.05 |
$26,990 |
D/D |
(1,171) |
344,145 |
|
- |
|
| Ellman Herman |
Senior V.P., Clinical Devel. |
• – – |
2010-09-22 |
4 |
S |
$23.05 |
$26,990 |
D/D |
(1,171) |
229,919 |
|
- |
|
| Credit Suisse First Boston |
10% Owner |
– – • |
2010-09-14 |
4 |
S |
$22.01 |
$2,745,383 |
I/I |
(124,717) |
26,123,651 |
|
- |
|
| Credit Suisse First Boston |
10% Owner |
– – • |
2010-09-13 |
4 |
S |
$22.05 |
$853,673 |
I/I |
(38,712) |
26,248,368 |
|
- |
|
| Credit Suisse First Boston |
10% Owner |
– – • |
2010-09-10 |
4 |
S |
$22.03 |
$2,419,103 |
I/I |
(109,800) |
26,287,080 |
|
- |
|
| Credit Suisse First Boston |
10% Owner |
– – • |
2010-08-20 |
4 |
D |
$0.00 |
$0 |
I/I |
(26,396,880) |
26,396,880 |
|
- |
|
| Bain Capital (wc) Netherlands B.v |
10% Owner |
– – • |
2010-08-13 |
3 |
IO |
$0.00 |
$0 |
I/I |
0 |
33,819,265 |
|
- |
|
| Bloem James H |
Director |
– • – |
2010-08-13 |
4 |
OE |
$16.01 |
$311,308 |
D/D |
19,176 |
24,176 |
|
- |
|
| Thl Wc (cayman), L.p. |
10% Owner |
– – • |
2010-07-29 |
3 |
IO |
$0.00 |
$0 |
I/I |
0 |
33,819,264 |
|
- |
|
| Gilligan Claire A |
Senior V.P. Global QualityOffi |
• – – |
2010-07-19 |
3 |
IO |
$0.00 |
$0 |
I/I |
0 |
37,335 |
|
- |
|
| Gilligan Claire A |
Senior V.P. Global QualityOffi |
• – – |
2010-07-19 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
56,511 |
|
- |
|
| Van Zoonen Marinus Johannes |
Pres., Europe/Intl&Glob. Mkt. |
• – – |
2010-03-31 |
4 |
A |
$0.00 |
$0 |
D/D |
5,621 |
23,342 |
|
- |
|
| Alpinvest Partners Later Stage Co-Investments Cust |
*See Remarks |
– – • |
2010-03-25 |
4 |
S |
$26.73 |
$6,145,013 |
D/D |
(229,892) |
3,175,150 |
|
- |
|
| Credit Suisse First Boston |
10% Owner |
– – • |
2010-03-25 |
4 |
S |
$25.19 |
$217,289,293 |
I/I |
(8,626,014) |
26,431,574 |
|
- |
|
| Bruno Anthony D |
Exec. V.P., Corp. Development |
• – – |
2010-01-29 |
4 |
A |
$0.00 |
$0 |
D/D |
22,970 |
690,850 |
|
- |
|
| Ellman Herman |
Senior V.P., Clinical Devel. |
• – – |
2010-01-29 |
4 |
A |
$0.00 |
$0 |
D/D |
6,090 |
231,090 |
|
- |
|
| Boissonneault Roger M |
CEO & President |
• • – |
2010-01-29 |
4 |
A |
$0.00 |
$0 |
D/D |
87,820 |
2,021,870 |
|
- |
|
| Hara Izumi |
Sr. VP, Gen. Counsel & Sec. |
• – – |
2010-01-29 |
4 |
A |
$0.00 |
$0 |
D/D |
6,690 |
236,013 |
|
- |
|
| Reichel W Carl |
President, Pharmaceuticals |
• – – |
2010-01-29 |
4 |
A |
$0.00 |
$0 |
D/D |
22,970 |
755,492 |
|
- |
|
| Cross Leland H |
Senior V.P., Tech. Operations |
• – – |
2010-01-29 |
4 |
A |
$0.00 |
$0 |
D/D |
6,090 |
345,316 |
|
- |
|
| Herendeen Paul |
Exec. V.P. and CFO |
• – – |
2010-01-29 |
4 |
A |
$0.00 |
$0 |
D/D |
22,970 |
764,996 |
|
- |
|
380 Records found
|
|
Page 11 of 16 |
|
|
